GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals
Executive Summary
Big pharmas' agreement could put consumer health where Pfizer wants, entirely in its rear-view mirror, and points GSK toward what it wants, more research and development funding freed up for the pharmaceutical ingredient operations that are its chief revenue drivers. All-equity deal, giving GSK 68% control and expected to close in 2019 second half, also likely will boost investors' confidence in the firms as both have been dogged by pressure to sell, spin-off or otherwise divest their consumer businesses.
You may also be interested in...
No More ‘Major’ Deals For GSK Consumer Before IPO – CEO Walmsley
GSK's CEO Emma Walmsley has effectively ruled out further big deals at its Consumer Healthcare unit before the business is separated from its parent through an IPO.
GSK And Pfizer Assemble Consumer Healthcare Leadership Team As JV Closes
Under Brian McNamara’s leadership, GSK Consumer Healthcare has begun to assemble a management team that combines talent from both GSK and Pfizer.
GSK And Pfizer Agree To Divest ThermaCare To Win EU Approval For JV
GSK and Pfizer must find a buyer for the global rights to the ThermaCare pain relief brand to receive European Commission approval for their proposed joint venture.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
